TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03897452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl (5 microgram/ml) prediluted ampoules
Description: Bolus; Fentanyl (5 microgram/ml) 0,5 microgram/kg (0.1 ml/kg) is administered over 1 min starting 3-5 min before the lighter skin breaking procedure.~Fentanyl (5 microgram/ml) 2 microgram/kg is administered over 10 min before the start of the more painful procedur ( pleura drainage or tracheal intubation).
Study: NCT00912314

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PTNS
Description: Monthly PTNS after 12 weeks of weekly PTNS
Study: NCT02292290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: 4 week lead-in 0.6mg Liraglutide OD up to 1.2mg OD after 2 weeks if poor response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: 4 week lead-in 0.6mg Liraglutide OD up to 1.2mg after two weeks if poor response.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfonylurea or Pioglitazone
Description: Addition to Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintain dual therapy (Sulf/Pio) as comparator to Liraglutide
Description: As per clinical guidelines for prescription
Study: NCT03510156

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior analytic treatment
Description: Function-based treatment
Study: NCT02270164

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artichoke Leaf Extract
Description: Capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule
Study: NCT02998801

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IPAD
Description: Patients undergoing surgery will watch the video using an PAD

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VR Goggles
Description: Patients undergoing surgery will watch the video using goggles
Study: NCT00424138

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FDG

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FDG

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FDG
Study: NCT04458753

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar focused exercises
Description: Transersus abdominis activation Multifidus activation Back extension exercise Curl up abdominal exercise
Study: NCT03589794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AP10-602
Description: Glucopyranosyl Lipid A -liposome-Quillaja Saponaria 21 (GLA-LSQ).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AP10-602
Description: Glucopyranosyl Lipid A -liposome-Quillaja Saponaria 21 (GLA-LSQ).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AP10-602
Description: Glucopyranosyl Lipid A -liposome-Quillaja Saponaria 21 (GLA-LSQ).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Malaria challenge
Description: Exposure to mosquitoes infected with P. falciparum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Malaria challenge
Description: Exposure to mosquitoes infected with P. falciparum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Malaria challenge
Description: Exposure to mosquitoes infected with P. falciparum.
Study: NCT03430440

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional mode
Description: PCA pumps typically set a fixed basal infusion rate to set the analgesic to enter at a constant rate every hour (conventional mode).
Study: NCT03589794

Intervention type: OTHER
Group type: OTHER
Intervention: Malaria challenge
Description: Exposure to mosquitoes infected with P. falciparum.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rCSP
Description: The rCSP malaria vaccine is a recombinant full-length P. falciparum circumsporozoite protein comprised of an amino terminus that binds heparin-sulfate proteoglycans, a four-amino-acid repeat region and a carboxy-terminus that contains a thrombospondin-like Type I region domain.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rCSP
Description: The rCSP malaria vaccine is a recombinant full-length P. falciparum circumsporozoite protein comprised of an amino terminus that binds heparin-sulfate proteoglycans, a four-amino-acid repeat region and a carboxy-terminus that contains a thrombospondin-like Type I region domain.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rCSP
Description: The rCSP malaria vaccine is a recombinant full-length P. falciparum circumsporozoite protein comprised of an amino terminus that binds heparin-sulfate proteoglycans, a four-amino-acid repeat region and a carboxy-terminus that contains a thrombospondin-like Type I region domain.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rCSP
Description: The rCSP malaria vaccine is a recombinant full-length P. falciparum circumsporozoite protein comprised of an amino terminus that binds heparin-sulfate proteoglycans, a four-amino-acid repeat region and a carboxy-terminus that contains a thrombospondin-like Type I region domain.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rCSP
Description: The rCSP malaria vaccine is a recombinant full-length P. falciparum circumsporozoite protein comprised of an amino terminus that binds heparin-sulfate proteoglycans, a four-amino-acid repeat region and a carboxy-terminus that contains a thrombospondin-like Type I region domain.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rCSP
Description: The rCSP malaria vaccine is a recombinant full-length P. falciparum circumsporozoite protein comprised of an amino terminus that binds heparin-sulfate proteoglycans, a four-amino-acid repeat region and a carboxy-terminus that contains a thrombospondin-like Type I region domain.
Study: NCT01738672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled nitrous oxide
Description: Administration of nitrous oxide for labor analgesia
Study: NCT00565721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluciclatide Injection - (AH111585 (F18))
Description: 18F labelled Cyclic RGD peptide PET agent for injection.
Study: NCT03672721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IA Carbo+ Radiation
Description: combination of intraarterial carboplatin + radiation in dose escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IA Carbo+ Radiation
Description: combination of intraarterial carboplatin + radiation in dose escalation
Study: NCT03414216

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group 2 - off-loading in fiberglass cast
Description: As above.
Study: NCT02899195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: On Day 1 of each 21 day cycle: Durvalumab 1120 mg IV will be administered before pemetrexed and cisplatin chemotherapy over approximately 60 minutes. Approximately 30 minutes after the durvalumab infusion is complete, pemetrexed 500 mg/m² IV will be administered over 10 minutes. Cisplatin 75 mg/m² IV over 2 hours will begin approximately 30 minutes after the end of pemetrexed administration. If carboplatin is substituted for cisplatin, carboplatin Area Under the Concentration-Time Curve (AUC) 5 will be infused over 30 minutes beginning approximately 15-30 minutes after the end of the pemetrexed administration. Maintenance: On Day 1 of each 21 day cycle: Durvalumab 1120 mg IV over approximately 60 minutes.
Study: NCT01921686

Intervention type: OTHER
Intervention: Sample collection and Questionnaire
Description: This is an observational biospecimen collection and questionnaire study. The subjects will be asked to complete a symptom questionnaire at screening visit. In addition, 3 esophageal biopsy samples will be taken to conduct laboratory analyses.

Intervention type: OTHER
Intervention: Sample collection and Questionnaire
Description: This is an observational biospecimen collection and questionnaire study. The subjects will be asked to complete a symptom questionnaire at screening visit. In addition, 3 esophageal biopsy samples will be taken to conduct laboratory analyses.

Intervention type: OTHER
Intervention: Sample collection and Questionnaire
Description: This is an observational biospecimen collection and questionnaire study. The subjects will be asked to complete a symptom questionnaire at screening visit. In addition, 3 esophageal biopsy samples will be taken to conduct laboratory analyses.
Study: NCT02658942

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ureteroscopy
Description: In Group A patients, Karl Storz Flex-X 7.5, FURS with a 365 µm laser fiber.
Study: NCT03672721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IA Carbo+ Radiation
Description: combination of intraarterial carboplatin + radiation in dose escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IA Carbo+ Radiation
Description: combination of intraarterial carboplatin + radiation in dose escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IA Carbo+ Radiation
Description: combination of intraarterial carboplatin + radiation in dose escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IA Carbo+ Radiation
Description: combination of intraarterial carboplatin + radiation in dose escalation
Study: NCT04135599

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a non-invasive, safe and easy-to-operate neuro-electrophysiological technique, which becoming an emerging therapeutic option for many mental disorders.It can modulate cortical excitability of target brain region, neuron plasticity and brain connections. Previous studies suggest that tDCS could reduce cue-induced craving and improve cognition in drug addiction.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a non-invasive, safe and easy-to-operate neuro-electrophysiological technique, which becoming an emerging therapeutic option for many mental disorders.It can modulate cortical excitability of target brain region, neuron plasticity and brain connections. Previous studies suggest that tDCS could reduce cue-induced craving and improve cognition in drug addiction.
Study: NCT02949544

Intervention type: OTHER
Group type: OTHER
Intervention: water immersion
Description: warm water immersion
Study: NCT00529152

Intervention type: DRUG
Group type: OTHER
Intervention: Deferiprone
Description: Ferriprox (deferiprone) oral solution will be given orally at a total daily dose of 75 mg/kg body weight or 100 mg/kg body weight, divided into 3 doses, for 24 weeks.
Study: NCT04301492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: 16 weeks for each participant. During the first visit a collection of medical and pharmacological history will be collected and ECG, laboratory tests and clinical assessment will be performed. After verifying the absence of significant abnormalities at the ECG and laboratory tests and after confirming all inclusion and exclusion criteria, subjects will perform the second visit to receive study drug (Brintellix drops 20 mg/ml). All subjects will be instructed to take Vortioxetine 1 drop every day after lunch, increasing of 1 drop per day arriving to 10 drops per day. After 5 days from the beginning of treatment, subject will be contacted by phone to check on tolerability and in absence of side effects, the dosage will be increased to 10 drops per day. At Week 4-8-12 patients will return to the site to perform all clinical evaluations required and to receive study drug.
Study: NCT01907750

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: biliary drainage tube
Study: NCT00695422

Intervention type: GENETIC
Intervention: polymerase chain reaction
Description: PCR for HPV DNA detection, performed on specimens collected at baseline, every 6 months while on parent protocol, treatment discontinuation on parent protocol, final visit on parent protocol.
Study: NCT04282343

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The DISCO App
Description: Patients will receive an individually-tailorable cancer treatment cost education and communication intervention delivered on an iPad just prior to meeting with their oncologist.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: Patients randomized to this arm will receive usual care.
Study: NCT02650804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPM31510 Nanosuspension Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study: NCT03080389

Intervention type: PROCEDURE
Intervention: Extended Urine Culture
Description: Extended Urine Culture Standard cultures will include 0.001 ml of specimen plated on sheep blood agar and MacConkey agar. Plates were inoculated and incubated at 35 degrees Celsius for 24 hours. Samples were considered positive if there were 10\^3 cfu or greater. The extended urine culture will be spun down by centrifuge (3000 rpm for 5 min) and 0.1 ml of the sediment will be cultured for 48 hours.~The participants will fill out the Bother, UDI-6, and PUF questionnaires before the cultures. If a patient has a positive urine culture, the patient will be asked to repeat the questionnaires 7-30 days post treatment with antibiotics. A comparison will be made between the standard and extended urine cultures to assess for a difference in identification and treatment of uropathogens.
Study: NCT01712763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: degarelix
Description: 180 women will be treated with degarlix 120 mg, in only one administration covering three months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Acetate 11.25 MG/ML (Enantone 11,25)
Description: 180 women will be treated with leuprolide acetate11.25 only once covering three months
Study: NCT03490123

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R1-Total community treatment with azithromycin
Description: At month 0, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R1-Total community treatment with azithromycin
Description: At month 0, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R2-Total community treatment with azithromycin
Description: At month 6, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R3-Total community treatment with azithromycin
Description: At month 12, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R2-Total targeted treatment with azithromycin
Description: At 6 months, study participants will be screened for active yaws. Participants with yaws and their contacts will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R3-Total targeted treatment with azithromycin
Description: At 12 months, study participants will be screened for active yaws. Participants with yaws and their contacts will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
Study: NCT03240003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GC-MRT
Description: Group 1 will receive a 4-week (8-sessions) course of GC-MRT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: modified GC-MRT
Description: group 3 will receive a 4-week (8-sessions) course of GC-MRT, modified

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-GC-MRT
Description: Group 2 will receive a 4-week (8-sessions) course of non-GC-MRT
Study: NCT01064973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arbaclofen
Description: A flexible dose titration will be utilized during the first four weeks to define the optimal titrated dose (OTD) for each subject. Investigators will use clinical judgment to adjust doses to the oral OTD. The starting dose will be 1 mg BID. The dose may be increased every four to five days to 2 mg BID, 3 mg BID, 5 mg BID and then 10 mg BID
Study: NCT02087085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 µg Brimonidine Implant
Description: 400 µg brimonidine implant in the study eye using Brimo DDS® applicator on Day 1, and every 3 months through Month 21.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham treatment with needleless applicator (no implant) to the study eye on Day 1, and every 3 months through Month 21.
Study: NCT04252872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP0605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP0605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1401
Study: NCT00695422

Intervention type: OTHER
Intervention: cytology specimen collection procedure
Description: Detection of HPV-associated neoplasia at baseline, every 6 months while on parent protocol, treatment discontinuation on parent protocol, final visit on parent protocol.

Intervention type: OTHER
Intervention: histological technique
Description: Detection of HPV-associated neoplasia at baseline, treatment discontinuation on parent protocol, final visit on parent protocol.
Study: NCT04252872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1401
Study: NCT00695422

Intervention type: PROCEDURE
Intervention: colposcopic biopsy
Description: Where observed during HRA, collection of tissue for detection of HPV-associated neoplasia at baseline, treatment discontinuation on parent protocol, final visit on parent protocol.
Study: NCT05659472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combination mindfulness spiritual-based cognitive therapy plus hypnosis
Description: The intervention was divided into eight components in eight sessions, namely (1) psychoeducation and intention, (2) awareness of breathing mindfulness, (3) body scan, (4) comfort training through daily activity/comfort exercises, (5) self-compassion / having a great soul with acceptance, gratitude, and sincerity, (6) planning happiness through independent healthy behavior targets, (7) independent healthy behavior (8) independent healthy behavior evaluation. Each therapeutic component of each session is further divided into three sub-components, namely psychoeducation, training, and hypnosis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy
Description: The program curriculum consists of the automatic pilot; living in our heads; gathering the scattered mind; recognizing aversion; allowing and letting be; thoughts as thoughts; kindness in action; maintaining and extending new learning.
Study: NCT02658942

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shockwave lithotripsy
Description: In Group B patients, a Siemens Lithostar Lithotriptor
Study: NCT02503787

Intervention type: DEVICE
Group type: OTHER
Intervention: Spinal Cord Stimulation (SCS)
Description: SCS programming options
Study: NCT01121081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alga Dunaliella Bardawil
Description: 4 capsules per day, 2 in the morning 2 in the evening for 3 month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Alga Dunaliella Bardawil~4 capsules per day, 2 in the morning 2 in the evening for 3 month
Study: NCT03831204

Intervention type: DEVICE
Intervention: biopac
Description: Acoustic cardiography was performed for all participants using the BIOPAC system with Student Lab software version 3.7.2. An electrocardiogram was obtained by two electrodes placed at the right upper limb and the lower left limb. Simultaneously heart sounds were recorded with a specific sensor placed at the mitral focus.

Intervention type: DEVICE
Intervention: biopac
Description: Acoustic cardiography was performed for all participants using the BIOPAC system with Student Lab software version 3.7.2. An electrocardiogram was obtained by two electrodes placed at the right upper limb and the lower left limb. Simultaneously heart sounds were recorded with a specific sensor placed at the mitral focus.

Intervention type: DIAGNOSTIC_TEST
Intervention: prognostic scores
Description: Effect and GWTGHF were calculated for every patient

Intervention type: DIAGNOSTIC_TEST
Intervention: prognostic scores
Description: Effect and GWTGHF were calculated for every patient
Study: NCT03026998

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI
Description: MRI will be performed each year during 10 years.
Study: NCT03068728

Intervention type: DEVICE
Group type: OTHER
Intervention: Arista

Intervention type: DEVICE
Group type: OTHER
Intervention: Nexfoam

Intervention type: DEVICE
Group type: OTHER
Intervention: Nasopore
Study: NCT01801904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: 6mg/kg IV given every 2 weeks until disease progression or unacceptable toxicity
Study: NCT03552848

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC
Description: MSC at a dose of 1000000 cells per kilogram of body weight will be given intravenously once every 4 days for 4 times
Study: NCT00895453

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: itraconazole
Description: 6-months maintenance regimen with monthly single-day itraconazole 200mg twice daily (bid)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: itraconazole
Description: 6-months maintenance regimen with monthly single-day itraconazole 200mg twice daily (bid)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lactobacillus gasseri
Description: Lactobacillus vaginal tablets monthly given through 6 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: classic homeopathy (carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, sepia M, etc. as prescribed)
Description: CH treatment was provided by a licensed CH practitioner. Specifically, a personal history was taken and an individualised treatment scheme was prescribed. The most often used homeopathic remedies were carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, and sepia M. Potencies of homeopathic remedies ranged from C 30 to C 1000.